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Summary
The use of whole blood gene expression to derive diagnostic biomarkers
capable of distinguishing between phenotypically similar diseases holds
great promise but remains a challenge. Differential gene expression analy-
sis is used to identify the key genes that undergo changes in expression
relative to healthy individuals, as well as to patients with other diseases.
These key genes can act as diagnostic, prognostic and predictive markers
of disease. Gene expression ‘signatures’ in the blood hold the potential to
be used for the diagnosis of infectious diseases, where current diagnostics
are unreliable, ineffective or of limited potential. For diagnostic tests
based on RNA signatures to be useful clinically, the first step is to identify
the minimum set of gene transcripts that accurately identify the disease in
question. The second requirement is rapid and cost-effective detection of
the gene expression levels. Signatures have been described for a number
of infectious diseases, but ‘clinic-ready’ technologies for RNA detection
from clinical samples are limited, though existing methods such as RT-
PCR are likely to be superseded by a number of emerging technologies,
which may form the basis of the translation of gene expression signatures
into routine diagnostic tests for a range of disease states.
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Introduction
The global analysis of the genome, the epigenome, the
transcriptome, the proteome and the metabolome, in the
context of various diseases, has led to the improvement
of our understanding of disease pathology and has
already started reforming disease diagnostics, with the
identification of a number of disease-specific ‘-omic’ sig-
natures. Analysing data in a high-throughput quantitative
manner has highlighted the way in which the host
responds to a number of pathogens. In this review, we
will focus on gene expression profiling and biomarker sig-
natures, specifically in the context of infectious diseases,
which remain among the leading causes of mortality and
disability worldwide. Globally, approximately 15 million
of 57 million (over 25%) annual deaths are estimated to
be related directly to infectious diseases.1 Newly emerging
and re-emerging pathogens constitute an urgent and
ongoing threat to public health throughout the world,
while large-scale, unnecessary use of antibiotics driven by
fear of missing severe bacterial infection contributes to
the growing problem of antimicrobial resistance. The
main focus of this review is diagnostic whole blood gene
expression signatures, and their translation into future
bedside point-of-care (POC) diagnostic tests.
Gene expression is the link between the genotype and
the phenotype of an organism, using the information
stored in the DNA to produce functional products
through transcription (functional RNA species) and trans-
lation (proteins).2 Even though information stored as
DNA is the same across the cells of an organism, the pat-
tern of genes that are expressed, their level of expression
and their isoforms differ between cells according to con-
ditions, so defining the physiological state of each cell.
Only a fraction of the approximately 30 000 genes
encoded in the human genome are expressed in a given
cell at a given time, defining the cell’s state. A variety of
mechanisms are employed to define which genes are tran-
scribed into RNA and which messenger RNAs (mRNAs)
are translated into proteins. The expression levels of a
specific gene can be quantified by detecting the presence
and measuring the abundance of the final product (either
the protein or functional RNA species) or its precursor
(typically mRNA). Measuring the amount of mRNA can
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act as a ‘proxy’ for the overall cellular activity at the
molecular level, enabling the elucidation of a patient’s
response to external stimuli, such as infection, and fur-
thering our understanding of the molecular regulatory
mechanisms that underlie disease.
Measuring gene expression
There are various methods for cellular RNA quantifica-
tion, each associated with a range of advantages and
disadvantages. Depending on the nature of the experi-
ment and the actual scientific questions posed, one
method may be preferable over the other. Reverse tran-
scription-quantitative polymerase chain reaction (RT-
qPCR) is the method of preference when a relatively
small previously identified set of genes are to be stud-
ied. It is still considered the ‘gold standard’ for RNA
quantification, making it preferable for validation stud-
ies. On the other hand, microarrays and RNA-sequen-
cing (RNA-seq) have made whole transcriptome analysis
possible, with arrays examining only the transcripts that
correspond to probes that are printed a priori on a
chip. The opportunities for novel transcript discovery
and splicing isoform detection, along with its wider
dynamic range, are the main biological reasons why
RNA-seq is superseding microarrays, despite its require-
ments for ample storage space, high-level data manage-
ment, as well as powerful computational infrastructure.3
Comparative analyses between RNA-seq and microarray
techniques have demonstrated that although a larger
proportion of genes identified as differentially expressed
by RNA-seq can be subsequently validated by RT-qPCR,
the two methods complement each other in transcrip-
tome profiling.4,5 Soon after next-generation sequencing
(NGS) was established, the third-generation sequencing
methods emerged (also known as single molecule
sequencing methods and next-next-generation sequenc-
ing). These methods are revolutionizing the life science
field in an unprecedented way by reducing the sequenc-
ing error rate, the time to results from days to hours,
and the overall cost per run.6,7 As far as the field of
transcriptomics is concerned, the impact is anticipated
to be particularly high because third-generation sequenc-
ing allows for direct sequencing of RNA molecules while
negating the need for cDNA synthesis and amplification
steps. Even though sequencing methods confer a natural
advantage, offering a wealth of information and the pos-
sibility for deeper exploration, gene expression microar-
rays have been addressing the identification of
differentially expressed genes successfully for many years.
They have enabled the elucidation of patients’ response
to pathogens, so furthering our understanding of the
molecular regulatory mechanisms that underlie infection
and disease (Fig. 1).
Sample composition
The aforementioned methods for measuring gene expres-
sion allow the identification of differentially expressed
genes between cells, tissues, disease states and treatments.
They are invaluable tools for shedding light on biological
processes and identifying the key molecules that allow
discrimination between different disease states.8 Various
models are employed to study the response to infection,
spanning from cell-line in vitro experiments and animal
models to studies of multi-level human responses.9 In
vitro host-response studies can monitor cells after the
exposure to the pathogen to unravel cell-specific mecha-
nisms underlying the host response to the pathogen. Cells
of preference can either be critical components of the
immune system (e.g. natural killer cells, T cells) or patho-
gen-specific target cell types and cell lines. Even though
in vitro approaches may not be able to fully describe the
transcriptional response of the host, they offer a con-
trolled environment and allow for examining changes in
expression over time.10–13 Other studies focus on analys-
ing the transcriptome of human tissue samples from the
site of the primary pathogen infection,14 with the capacity
to preserve the histological context of the affected tis-
sue.15
These approaches can be of high value when the interest
is unravelling the biology or the identification of disease
stages. However, to identify biomarkers that can be of
clinical significance, it is important to determine patterns
of gene expression in easily accessible bodily fluids, such
as nasopharyngeal secretions and peripheral whole blood
from human patient samples. As distinct patterns of gene
expression have been associated with different infectious
diseases and disease stages, these patterns allow distinction
between patients affected by a disease from healthy con-
trols or between patients with different diseases.16
Blood is not only an accessible tissue, permitting inves-
tigation of candidate biomarkers, but blood cells interact
with many other tissues of the body, playing a key role in
transportation of oxygen, nutrients and waste, as well as
in immunity, inflammation, signalling and defence.
Molecular profiling of circulating blood cells reflects
physiological and pathological events occurring in various
different tissues of the body. Hence, whole blood gene
expression profiling is not only a means of exploring
multiple physiological processes, but also a means of
identification of gene expression patterns that offers a
broad picture of the organism’s health state and overall
immunity. Peripheral blood cells share > 80% of the tran-
scriptome with brain, colon, heart, kidney, liver, lung,
prostate, spleen and stomach.17 Hence, it has been feasi-
ble to derive distinct host response signatures for a vari-
ety of diseases from transcriptional profiling of peripheral
blood.
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Populations and patient characterization
The most pivotal components of human biomarker
studies are the experimental design and the clinical
recruitment. A widely practiced approach to ensure
robustness and reproducibility is to identify biomarkers
in a ‘discovery’ patient group, and reproduce findings
in an independent ‘validation’ group. Rigorous patient
phenotyping in both the discovery and validation
groups, using carefully curated data based on the best
available tests, is required because a small proportion
of false assignment, particularly in the discovery group,
can skew correct biomarker identification.18,19 Although
strict inclusion criteria can increase the likelihood that
signatures are trained on accurately phenotyped
patients, this can be difficult to achieve, particularly
where the need for novel biomarkers is made pressing
by the lack of an available perfect ‘gold-standard’ test.
This is particularly true for tuberculosis, which is asso-
ciated with non-specific symptoms and diagnostic tests
that yield positive results that do not necessarily rule
out latent tuberculosis infection.20 Recruitment for these
studies should be conducted among the most relevant
populations, to ensure that the discovery cohort is rep-
resentative of the population at which the biomarker
tests are aimed. In cases where a gene expression signa-
ture should be applicable regardless of background
endemic infections or HIV infection, both rural and
urban populations should be recruited, as well as HIV-
infected and -uninfected participants.21,22 These should
then be stratified between groups in addition to age,
gender and other factors that may influence clinical
presentation, diagnostic workflows and the sample’s cel-
lular composition, which should be considered in the
analytical pipeline.
Bioinformatics analysis and signature
identification
Gene expression microarrays and, more recently, RNA-
seq enable transcriptional profiling of large cohort sizes in
a high-throughput manner, providing highly dimensional
data sets that require sophisticated bioinformatics analysis
to process and understand. Biomarker signatures identi-
fied in the last few years have mostly been derived from
microarray data; however, RNA-seq is emerging as a tech-
nique that is rapidly replacing microarrays. It permits
hypothesis-free experimental design, detection of novel
transcripts and alternative splicing, gene fusion and allele-
specific expression, while also allowing for simultaneous
sequencing of pools of transcripts that may come from
different organisms and coexist in the same environment,
termed meta-transcriptomics.23,24 This is pivotal in study-
ing infection because it allows unravelling of the dynamic
interplay between the host and the interacting organisms
by measuring their altered gene expression patterns
simultaneously. 25
Four main steps constitute the analytical pipelines of
gene expression biomarker studies, with many variations
according to the experimental needs: (i) data quality con-
trol and pre-processing, (ii) gene biomarker selection,
(iii) prediction model implementation and (iv) perfor-
mance evaluation. Although more complicated post-
experimental data analysis is needed for the RNA-seq
data,26 once the expression data are pre-processed,
machine-learning methodology leverages the analytical
biomarker identification pipeline and prediction assess-
ment workflow downstream. Due to the large number of
candidate biomarkers measured and the duplicated infor-
mation for classification they may provide, the choice of
feature (biomarker) selection algorithm is crucial. There
is a plethora of feature selection and classification meth-
ods that are employed in combination by the computa-
tional community to address the problems that gene
expression analysis poses.27 In some cases, feature selec-
tion can be embedded in the learning algorithms, for
example in penalized regression models (elastic net,
LASSO) and decision trees.
The goal remains the identification of the smallest pos-
sible set of non-redundant genes with the best possible
predictive performance that can be maximally repro-
ducible. Therefore, different functions and metrics are
used to evaluate the performance of biomarkers regarding
their ability to discriminate between patient groups.
Receiver operating characteristic curves are a fundamental
tool for evaluating the signatures’ diagnostic performance,
whereas positive and negative predictive values incorpo-
rate the prevalence of the disease in difference settings in
the evaluation.28–31 Importantly, as signature derivation
can be influenced by population selection, sample han-
dling, quantification approaches and analytical tools,
external validation in different populations, using alterna-
tive quantification methods, is instrumental.
Translation of gene expression signatures into
diagnostic, prognostic and theranostic tools
Gene expression signatures derived from whole blood
have been reported for several diseases including bacterial
and viral infections32–34 as well as pathogen-specific dis-
eases including malaria,35,36 typhoid fever,37,38 dengue
virus infection,23 HIV infection,34 human respiratory syn-
cytial virus infection,24 tularaemia39 and tuberculo-
sis.21,22,40 Recently, new parsimonious approaches32 as
well as multi-cohort meta-analyses41 have identified gene
expression signatures comprising minimal numbers of
genes, paving the way for easier translation into cost-
effective clinical diagnostic tests.41
It is envisaged that the gene expression signatures
described above can be used to diagnose diseases, track
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disease progression and monitor treatment efficacy.40
Gene expression signatures could enhance earlier disease
diagnosis, before the onset of disease symptoms. Earlier
diagnosis of infectious diseases improves treatment out-
comes and may prevent onwards transmission. Translat-
ing gene expression signatures into diagnostic, prognostic
or theranostic (i.e. therapy guiding) biomarkers requires
clinically useable technology for reliable and reproducible
measurement of gene expression. In oncology, gene
expression signatures are already being used to distinguish
between tumour types, identify the stage of cancer, and
predict the efficacy of administering certain therapeutics.
For example, the MammaPrint Assay analyses the expres-
sion of a set of 70 genes, and can indicate the probability
of breast cancer recurring in a given patient.42 This assay
involves microarray analysis of tumour sample cDNA.
However, this is a relatively costly assay that requires
sophisticated laboratory infrastructure and highly trained
personnel.
For gene expression signatures to be translated into
diagnostic tools used in routine clinical practice, a reduc-
tion in cost and processing requirements is needed. One
of the most likely ways of achieving this will involve a
move from microarray-based assays towards using RT-
qPCR and related technologies, combined with analysis
software that will be able to give a simple readout indi-
cating the disease probability score, based on the concen-
tration of each of the transcripts that comprise a disease
signature. Although measuring gene expression using RT-
qPCR on a routine basis would be costly and require
highly skilled laboratory technicians, it may be appropri-
ate for use in resource-rich laboratory settings, provided
it is of significant clinical value. Just as gene expression
signatures are typically discovered using quantification
relative to either a reference gene or other genes, relative
quantification of the transcripts will be more feasible to
implement than absolute quantification. In addition, the
added information provided by absolute quantification
will be of little clinical use. However, quantification rela-
tive to an appropriate reference gene will be important to
normalize expression values between individuals and
RNA extraction processes (Fig. 1).
A range of devices that allow for automation of PCR and
RT-PCR have been developed in recent years. Although
most of these are designed for the detection of pathogen
genomic DNA and RNA, they could potentially be devel-
oped for use in gene expression analysis, provided they
allow for sensitive, quantitative detection of mRNA. An
example of an automated PCR machine is Cepheid’s Gene
Xpert system, which allows for the sensitive detection of
pathogen genomic DNA, and now RNA.43 The advantages
of this system include sample processing within each car-
tridge, fully automated PCR and a ‘plug and play’ system,
where different samples and pathogen species can be exam-
ined simultaneously. Similarly, Roche’s cobas Liat RT-
PCR System has been used for the detection of viral RNA
at the POC.44 This system involves bench-top multiplex
RT-PCR analysis of, for example, nasopharyngeal swabs for
respiratory pathogens. However, like Roche’s cobas Liat
RT-PCR System, this is not quantitative. FilmArray,
developed by bioMerieux (Marcy l’Etoile, France), is a
multiplex PCR system that integrates sample extraction
and preparation, amplification and detection. With a turn-
around time of approximately 1 hr, and minor manual
requirements, this represents a promising platform to
which gene expression signatures could be applied. The
automated sampling process involves extraction and purifi-
cation of nucleic acids from unprocessed PAXgene Blood
RNA Tube samples, which is followed by nested multiplex
PCR. The reported sensitivity is 85–100%, depending on
the nucleic acid target. However, this technology is cur-
rently used to detect pathogen DNA and has not been used
for RT-PCR, nor is it quantitative. bioMerieux has also
developed two technologies that provide quantitative
detection of RNA. Argene performs RT-PCR to detect
viral RNA, and sample extraction can be automated. How-
ever, the time to result is 35 hr, and so this would not be
applicable to POC settings. Although it can perform RT, it
has not been used for the detection of mRNA, which may
be less abundant than viral RNA. Although promising, the
sensitivity and quantification capabilities of these technolo-
gies are currently unproven for clinical diagnostic testing
using gene expression signatures.
Although the cost and time required for NGS has fallen
significantly in recent years, few NGS technologies have
been applied for clinical diagnostics, and even fewer for
gene expression analysis. However, in contrast to previous
technologies, NGS offers flexible open platforms for
simultaneous detection of nucleic acids from both the
host and the pathogen, which can facilitate even more
accurate disease diagnosis. A key recent advance in NGS
is the development of Oxford Nanopore’s MinION
sequencer, which allows for portable and affordable
sequencing (Oxford Science Park, Oxford, UK). The
MinION has been used for the epidemiological surveil-
lance of the Ebola virus 45 and more recently the Zika
virus in field settings.46 As results are semi-quantitative,
and Oxford Nanopore have now announced that it is
possible to sequence RNA using the MinION, this tech-
nology holds great potential as a new contender in gene
expression analysis in close to POC settings.
Isothermal amplification
Although RT-qPCR is the reference standard method for
gene expression analysis, its use at the POC is limited by
the requirement for a thermocycler and complex data
analysis. In contrast, isothermal amplification techniques,
which are typically conducted at one specified tempera-
ture, do not require thermocycling and so have fewer
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equipment requirements. Isothermal amplification nucleic
acid detection strategies are attractive for molecular POC
diagnostics, and can be achieved in a number of ways,
each exploiting the presence of target RNA or DNA to
trigger certain processes, such as:
• Primer extension, followed by a mechanism that frees
the template (target), allowing it to be recycled and
used again for primer extension (e.g. helicase displace-
ment assay, strand displacement assay)
• Toehold-mediated strand displacement or hybridiza-
tion to a hairpin loop or two DNA probes, that leads
to a change in secondary structure (such as the forma-
tion of a G-quadruplex, which has a peroxidase-like
catalytic function)
• Hybridization of two DNA probes that can then be
ligated (e.g. ligase chain reaction)
• The aggregation of DNA probes, providing a ratiomet-
ric increase in signal (e.g. branched DNA assays)
Some isothermal amplification strategies, such as loop-
mediated isothermal amplification, rolling circle amplifi-
cation, strand displacement amplification and helicase
dependent amplification, require a DNA template to pro-
ceed. Detection of mRNA using these strategies would
therefore require an initial reverse transcription step
before the amplification reaction. Others, such as nucleic
acid sequence-based amplification and exponential ampli-
fication reaction are able to use RNA sequences as the
template for amplification and therefore negate the
requirement of the RT step. The AlereTM i-technology uses
a type of isothermal amplification called nicking enzyme
amplification reaction, which uses RNA as a direct target
and has a turnaround time of < 15 min.47 Isothermal
amplification strategies have numerous advantages com-
pared with PCR, but it should be noted that lack of
specificity is a key issue in the design of such assays and
should be a major consideration in their use for gene
expression analysis.
Pathogens
Under-expression
Over-expression
Differential stimulation
of host inflammatory cells
Pathogen-specific gene expression
signatures of the host
Gene expression
changes in
the host’s blood
Gene expression
changes in
the host’s blood
Biomarker
genes
Biomarker
genes
Pathogen infects host, e.g. viral infection
Pathogen infects host, e.g. bacterial infection
Figure 1. Different pathogens elicit different host transcriptomic responses that can be measured from whole blood.
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Emerging technologies
Many emerging technologies could enable sensitive, yet also
quantitative, detection of gene expression signatures for
diagnostic purposes. Many emerging techniques and mate-
rials have been employed for the detection of nucleic acids,
such as electrochemical detection,48,49 microfluidic-based
lab-on-a-chip devices,50–52 nanomaterials53,54 and the
recently introduced Oxford Nanopore MinION sequencing
platform complemented by real-time bioinformatics ana-
lytical tools.55–57 In addition, molecular based methods are
rapidly emerging. For example, the re-purposing of
CRISPR-based systems for highly specific and sensitive
detection of RNA and DNA was recently demonstrated.
The ‘SHERLOCK’ (Specific High-Sensitivity Enzymatic
Reporter unLOCKing) platform successfully detected low
quantities of pathogen and human RNA/DNA, with single
base mismatch specificity. It is not yet clear whether this
system has the quantitative accuracy required to compare
relative expression levels of multiple genes, which would be
needed for the interrogation of host RNA signatures.58
Nanomaterials are a large and growing class of materials
that are now being used to make extraordinarily sensitive
diagnostic tests. There is a multitude of nanomaterials that
can be used for the purposes of RNA sensing, including
gold nanoparticles (AuNPs),59 silica nanoparticles,60 mag-
netic nanoparticles61 and electrochemically active nanoma-
terials such as zinc oxide.62 Of these, AuNPs are the best
characterized and understood. The ease with which AuNPs
can be functionalized with antibodies, and their strong red
colour, has made them an important component of
immunochromatography assays, also known as lateral flow
tests. These are generally low-cost, paper-based devices that
satisfy many of the ASSURED criteria for POC diagnostic
tests.63,64 However, although these types of test are appro-
priate for immunoassays, their application for nucleic acid
detection is more challenging. Although isothermal ampli-
fication assays can be conducted on paper,65 these tests are
generally for nucleic acid detection alone, whereas quanti-
tative analysis of nucleic acid concentration has yet to be
achieved.
Fluorescence-based homogeneous assays that require no
washing steps represent a promising alternative for quanti-
tative detection of nucleic acids at the POC. Fluorescent
nanoparticles, such as quantum dots (QDs), have been
used for these purposes due to their bright fluorescence
and amenability to multiplexing. A homogeneous, QD-
based RNA sensing assay was recently reported, which gave
a fluorescent readout in proportion to the concentration of
target RNA present.53 Traditionally, these signals would
need to be recorded using costly fluorescence spectroscopy
methods, which is not suitable for use in POC settings.
However, recent advances in digital camera technology, as
well as the increased availability of blue LEDs and lasers,66
have resulted in dramatically reduced costs for fluorescence
imaging systems. In 2012, Xie et al.67 showed that it was
possible to detect the Mycobacterium tuberculosis-specific
enzyme BlaC in sputum using the camera of a cell phone,
using a simple LED as a light source. BlaC-specific fluoro-
genic substrates were designed, which showed a 100-fold
increase in fluorescence intensity in the presence of BlaC.
More recently, QD fluorescence was measured using an
LED to excite the QDs, capturing emission with a smart-
phone camera and analysing fluorescence intensity with a
custom-made smartphone application.68 The powerful
cameras of current mobile phone technology mean that the
results of fluorescence-based tests can be analysed by
mobile phones and translated into user-friendly, portable
and low-cost devices.69
A novel advance in gene expression analysis was per-
formed by Geiss et al.,54 who reported in 2008 the devel-
opment of the NanoString nCounter system to detect
multiple mRNA transcripts. Colour-coded probe pairs
were able to hybridize with complementary mRNA,
resulting in tripartite structures made up of the target
mRNA, a specific reporter probe and a capture probe.
Affinity purification results in capture on a surface. Fol-
lowing immobilization, fluorescence imaging was able to
reveal the order of fluorescent segments in the colour-
coded reporter probes, allowing the calculation of the
concentration of a particular mRNA transcript. Detection
limits of below 05 fM were reported, and the linear
dynamic range was over 500-fold. NanoString technology
has been used successfully in the diagnosis of patients
with raised interferon response genes (Aicardi–Goutieres
syndrome),70 and for the profiling of children with septic
shock.71 However, this method relies on sophisticated
equipment, which would be inappropriate for use at or
near to POC settings. It may, however, be useful for the
detection of extremely low-level transcripts where the
technology is readily available, and for diagnosis of condi-
tions without alternative accurate tests, where rapid turn-
around times are not required.
Various challenges remain for the nanodiagnostics field,
particularly with regards to optimizing the surface chem-
istry of nanomaterials in order to achieve greater pre-
dictability of their behaviour and avoid undesirable
interactions with other biomolecules that may be present
in complex matrices. A key challenge for the QD field is
the toxicity of the chemicals that make up QD cores,
which are typically heavy metals, such as cadmium sele-
nide, that consequently must be handled and disposed of
with care. Risks are mitigated by the minute amounts
required for diagnostic assays and by using newly devel-
oped QDs that do not contain heavy metals. These QDs
are composed of small organic molecules and polymers
(p-dots) and so show lower toxicity than their heavy
metal counterparts, yet retain their extraordinary optical
properties.72 Given these advances, it is evident that
combining the advantageous optical properties of
ª 2017 The Authors. Immunology Published by John Wiley & Sons Ltd., Immunology, 153, 171–178176
H. D. Gliddon et al.
nanomaterials with programmable molecular biology
approaches such as isothermal amplification could enable
the design of a new class of sensitive, robust and versatile
diagnostic tests.
Sample to answer: a promising reality or a long
way off?
As the majority of gene expression analysis studies are
based on RNA isolated from whole blood, this is the
most likely analytical sample that could be used for
detecting gene expression signatures. Importantly, geno-
mic DNA, which shares sequence homology with the
transcripts comprising gene expression signatures, is
removed, as well as many molecules that could interfere
with mRNA detection assays. In addition, most mRNA is
intracellular, and so a cell lysis step would be necessary
for their detection. RNA is less stable than DNA and can
be degraded by endogenous RNases, which are present on
the skin as well as in blood and tissue. Careful handling
of samples is therefore essential to conserve RNA integ-
rity. RNA is usually purified from whole blood by first
using a detergent to lyse cells and proteinase K to degrade
proteins. Following the addition of ethanol or iso-
propanol, which precipitates nucleic acids, this lysed sam-
ple is typically applied to a column, which specifically
binds to nucleic acids. After a washing step, a DNase is
applied to the column, which hydrolyses the genomic
DNA that has bound to it. The RNA can then be eluted
by dissolving it in an appropriate solvent. RNase inhibi-
tors are often present throughout this process to prevent
RNA degradation.73
Current techniques for RNA purification are labour-
intensive and ill-suited to POC or resource-limited set-
tings. However, available technologies that detect tran-
script abundance are amenable to use in diagnostic
laboratories, and existing technologies including qPCR
and NanoString are being adopted for diagnostic testing
of infectious and non-infectious conditions where the
accurate rather than rapid diagnostic testing is needed.
Recent studies have shown that microfluidic devices can
be used to perform a one-step RNA purification and RT-
PCR assay, with minimal input from laboratory person-
nel.52 In future, these sample preparation processes will
require less time and handling and may prove to be suffi-
ciently robust to be used routinely.
Conclusion
As we continue to explore the most reliable biomarkers
and their translation into routine diagnostic tests, there is
growing insight to consider from the initial study design
to the level of molecular detection. In recent years,
numerous methodologies have emerged for measuring
gene expression biomarkers that make their translation
into practice more feasible. Although there are still many
hurdles to overcome in the introduction of gene expres-
sion biomarkers into mainstream clinical decision-mak-
ing, the next decade will probably see the advent of gene
expression signatures as diagnostic biomarkers in clinical
practice for a range of diseases.
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